| Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
 Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
  
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 
  free 
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
  free 
  free 
   English Wikipedia
 
 Nephropedia Template TP (
 
 Twit Text
 
 
 DeepDyve
 Pubget Overpricing
 | lüll   
 
 Ras in cancer and developmental diseases Fernandez-Medarde A; Santos EGenes Cancer  2011[Mar]; 2 (3): 344-58Somatic, gain-of-function mutations in ras genes were the first specific genetic  alterations identified in human cancer about 3 decades ago. Studies during the  last quarter century have characterized the Ras proteins as essential components  of signaling networks controlling cellular proliferation, differentiation, or  survival. The oncogenic mutations of the H-ras, N-ras, or K-ras genes frequently  found in human tumors are known to throw off balance the normal outcome of those  signaling pathways, thus leading to tumor development. Oncogenic mutations in a  number of other upstream or downstream components of Ras signaling pathways  (including membrane RTKs or cytosolic kinases) have been detected more recently  in association with a variety of cancers. Interestingly, the oncogenic Ras  mutations and the mutations in other components of Ras/MAPK signaling pathways  appear to be mutually exclusive events in most tumors, indicating that  deregulation of Ras-dependent signaling is the essential requirement for  tumorigenesis. In contrast to sporadic tumors, separate studies have identified  germline mutations in Ras and various other components of Ras signaling pathways  that occur in specific association with a number of different familial,  developmental syndromes frequently sharing common phenotypic cardiofaciocutaneous  features. Finally, even without being a causative force, defective Ras signaling  has been cited as a contributing factor to many other human illnesses, including  diabetes and immunological and inflammatory disorders. We aim this review at  summarizing and updating current knowledge on the contribution of Ras mutations  and altered Ras signaling to development of various tumoral and nontumoral  pathologies.ä
 |